

# Francesco Cognetti

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8149666/francesco-cognetti-publications-by-year.pdf>  
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

217 papers	13,977 citations	51 h-index	115 g-index
222 ext. papers	16,266 ext. citations	6.6 avg, IF	5.6 L-index

#	Paper	IF	Citations
217	Narrative medicine: feasibility of a digital narrative diary application in oncology.. <i>Journal of International Medical Research</i> , <b>2022</b> , 50, 3000605211045507	1.4	0
216	Rapid decline of humoral response to two doses of BNT162b2 vaccine in patients with solid cancer after six months: The urgent need of the additional dose!. <i>European Journal of Cancer</i> , <b>2022</b> , 165, 169-173	7.5	2
215	Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer. <i>Molecular Cancer</i> , <b>2021</b> , 20, 151	42.1	1
214	Exploring CT Texture Parameters as Predictive and Response Imaging Biomarkers of Survival in Patients With Metastatic Melanoma Treated With PD-1 Inhibitor Nivolumab: A Pilot Study Using a Delta-Radiomics Approach. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 704607	5.3	2
213	Systemic effect of radiotherapy before or after nivolumab in lung cancer: an observational, retrospective, multicenter study. <i>Tumori</i> , <b>2021</b> , 3008916211004733	1.7	1
212	Precision Medicine and Melanoma: Multi-Omics Approaches to Monitoring the Immunotherapy Response. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	6
211	The first report on coronavirus disease 2019 (COVID-19) vaccine refusal by patients with solid cancer in Italy: Early data from a single-institute survey. <i>European Journal of Cancer</i> , <b>2021</b> , 153, 260-264	7.5	20
210	Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 620-631	21.7	58
209	Oligometastatic Breast Cancer: How to Manage It?. <i>Journal of Personalized Medicine</i> , <b>2021</b> , 11,	3.6	2
208	Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer. <i>Npj Breast Cancer</i> , <b>2021</b> , 7, 82	7.8	0
207	Eribulin in brain metastases of breast cancer: outcomes of the EBRAIM prospective observational trial. <i>Future Oncology</i> , <b>2021</b> , 17, 3445-3456	3.6	1
206	Reply to the letter entitled: Re: The first report on Covid-19 vaccine refusal by patients with cancer in Italy: Early data from a single-institute survey. <i>European Journal of Cancer</i> , <b>2021</b> , 158, 253-254	7.5	1
205	Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 1458-1467	21.7	7
204	The clinician's perspective on the 21-gene assay in early breast cancer.. <i>Oncotarget</i> , <b>2021</b> , 12, 2514-2530	3.3	1
203	p53 and BCL2 Immunohistochemical Expression Across Molecular Subtypes in 1099 Early Breast Cancer Patients With Long-Term Follow-up: An Observational Study. <i>Clinical Breast Cancer</i> , <b>2020</b> , 20, e761-e770	3	3
202	Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 202	5.3	3
201	Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial. <i>European Journal of Cancer</i> , <b>2020</b> , 136, 43-51	7.5	3

200	Nanoparticle albumin-bound paclitaxel/liposomal-encapsulated doxorubicin in HER2-negative metastatic breast cancer patients. <i>Future Oncology</i> , <b>2020</b> , 16, 1629-1637	3.6	2
199	Comparison of 18F-FDG PET/CT Criteria for the Prediction of Therapy Response and Clinical Outcome in Patients With Metastatic Melanoma Treated With Ipilimumab and PD-1 Inhibitors. <i>Clinical Nuclear Medicine</i> , <b>2020</b> , 45, 187-194	1.7	17
198	From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer. <i>Cells</i> , <b>2020</b> , 9,	7.9	14
197	Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial. <i>International Journal of Cancer</i> , <b>2020</b> , 147, 160-169	7.5	6
196	T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study. <i>Clinical Breast Cancer</i> , <b>2020</b> , 20, e181-e187	3	24
195	Five-Year Outcomes With Nivolumab in Patients With Wild-Type Advanced Melanoma. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3937-3946	2.2	39
194	Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy. <i>Cancers</i> , <b>2020</b> , 12,	6.6	28
193	PTEN Function at the Interface between Cancer and Tumor Microenvironment: Implications for Response to Immunotherapy. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	12
192	BRAF status modulates Interleukin-8 expression through a CHOP-dependent mechanism in colorectal cancer. <i>Communications Biology</i> , <b>2020</b> , 3, 546	6.7	1
191	Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study. <i>European Urology Oncology</i> , <b>2019</b> , 2, 699-707	6.7	19
190	The unmet need for oncofertility preservation in women: Results of a survey by different oncological specialists in Lazio, Italy. <i>Current Problems in Cancer</i> , <b>2019</b> , 43, 100479	2.3	1
189	Advances in Tumor-Stroma Interactions: Emerging Role of Cytokine Network in Colorectal and Pancreatic Cancer. <i>Journal of Oncology</i> , <b>2019</b> , 2019, 5373580	4.5	11
188	Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials. <i>Gynecologic Oncology</i> , <b>2019</b> , 154, 83-88	4.9	4
187	Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program <b>2019</b> , 7, 99		71
186	PTEN as a Prognostic/Predictive Biomarker in Cancer: An Unfulfilled Promise?. <i>Cancers</i> , <b>2019</b> , 11,	6.6	53
185	Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. <i>BJU International</i> , <b>2019</b> , 123, 98-105	5.6	48
184	Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases. <i>Anticancer Research</i> , <b>2019</b> , 39, 4265-4271	2.3	19
183	A multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: clinical benefit is a plausible end point?. <i>Future Oncology</i> , <b>2019</b> , 15, 1717-1727	3.6	0

182	Phase II study of weekly carboplatin in pretreated adult malignant gliomas. <i>Journal of Neuro-Oncology</i> , <b>2019</b> , 144, 211-216	4.8	1
181	Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer. <i>European Journal of Cancer</i> , <b>2019</b> , 123, 72-80	7.5	34
180	Colorectal cancer stem cells properties and features: evidence of interleukin-8 involvement. <b>2019</b> , 2, 968-979		0
179	Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials. <i>Cancers</i> , <b>2019</b> , 11,	6.6	26
178	Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer <b>2019</b> , 7, 316		56
177	RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2019</b> , 38, 12	12.8	66
176	Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial. <i>JAMA Oncology</i> , <b>2019</b> , 5, 187-194	13.4	173
175	Adjuvant vemurafenib in resected, BRAF mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 510-520	21.7	123
174	Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 474-485	21.7	39
173	mTOR Cross-Talk in Cancer and Potential for Combination Therapy. <i>Cancers</i> , <b>2018</b> , 10,	6.6	78
172	Activity of Eribulin Mesylate in Brain Metastasis from Breast Cancer: A Stone in a Pond?. <i>Oncology</i> , <b>2018</b> , 94 Suppl 1, 29-33	3.6	5
171	Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2018</b> , 37, 140	12.8	22
170	T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer. <i>Breast</i> , <b>2018</b> , 41, 137-143	3.6	26
169	Role of mTOR Signaling in Tumor Microenvironment: An Overview. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	74
168	A randomized, open label, multicenter phase 2 study, to evaluate the efficacy of sorafenib (So) in patients (pts) with metastatic renal cell carcinoma (mRCC) after a radical resection of the metastases: RESORT trial.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 4502-4502	2.2	6
167	Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 1146-1155	8.9	57
166	Impressive Long-term Response with Pertuzumab and Trastuzumab in HER2-positive Breast Cancer with Brain Metastasis. <i>In Vivo</i> , <b>2018</b> , 32, 839-842	2.3	0
165	PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer. <i>Scientific Reports</i> , <b>2017</b> , 7, 43013	4.9	36

164	Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting. <i>Oncologist</i> , <b>2017</b> , 22, 648-654	5.7	8
163	The course of cancer related fatigue up to ten years in early breast cancer patients: What impact in clinical practice?. <i>Breast</i> , <b>2017</b> , 34, 44-52	3.6	44
162	Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. <i>European Journal of Cancer</i> , <b>2017</b> , 82, 237-246	7.5	30
161	Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies. <i>European Journal of Cancer</i> , <b>2017</b> , 71, 34-42	7.5	31
160	Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , <b>2017</b> , 18, 1274-1284	21.7	913
159	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , <b>2017</b> , 18, 1688-1700	21.7	328
158	Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate. <i>Anti-Cancer Drugs</i> , <b>2017</b> , 28, 110-115	2.4	4
157	Lack of growth inhibitory synergism with combined MAPK/PI3K inhibition in preclinical models of pancreatic cancer. <i>Annals of Oncology</i> , <b>2017</b> , 28, 2896-2898	10.3	9
156	Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?. <i>Future Oncology</i> , <b>2017</b> , 13, 2791-2797	3.6	19
155	Efficacy and safety of T-DM1 in the Real-world practice of HER2+ advanced breast cancer setting: a multicenter study. <i>Oncotarget</i> , <b>2017</b> , 8, 64481-64489	3.3	15
154	Gender effects of single nucleotide polymorphisms and miRNAs targeting clock-genes in metastatic colorectal cancer patients (mCRC). <i>Scientific Reports</i> , <b>2016</b> , 6, 34006	4.9	13
153	Palbociclib: efficacious but predictive biomarkers still needed. <i>Lancet Oncology</i> , <b>2016</b> , 17, 402-403	21.7	1
152	First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2016</b> , 35, 104	12.8	29
151	Nivolumab in previously untreated melanoma without BRAF mutation. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 320-30	59.2	3809
150	Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2x2 factorial, randomised phase 3 trial. <i>Lancet</i> , <b>2015</b> , 385, 1863-72	40	131
149	PTEN: Multiple Functions in Human Malignant Tumors. <i>Frontiers in Oncology</i> , <b>2015</b> , 5, 24	5.3	284
148	Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis. <i>Critical Reviews in Oncology/Hematology</i> , <b>2015</b> , 93, 50-9	7	11
147	Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients. <i>Drug Design, Development and Therapy</i> , <b>2015</b> , 9, 6177-83	4.4	16

146	Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice. <i>Future Oncology</i> , <b>2015</b> , 11, 431-8	3.6	15
145	Metastatic pancreatic cancer: Is there a light at the end of the tunnel?. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 4788-801	5.6	48
144	Targeting bone metastatic cancer: Role of the mTOR pathway. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , <b>2014</b> , 1845, 248-54	11.2	21
143	Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. <i>Journal of Neuro-Oncology</i> , <b>2014</b> , 118, 109-16	4.8	90
142	PTEN expression and function in adult cancer stem cells and prospects for therapeutic targeting. <i>Advances in Biological Regulation</i> , <b>2014</b> , 56, 66-80	6.2	71
141	Clinical experience with ipilimumab 3mg/kg: real-world efficacy and safety data from an expanded access programme cohort. <i>Journal of Translational Medicine</i> , <b>2014</b> , 12, 116	8.5	130
140	KRAS early testing: consensus initiative and cost-effectiveness evaluation for metastatic colorectal patients in an Italian setting. <i>PLoS ONE</i> , <b>2014</b> , 9, e85897	3.7	10
139	Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program. <i>Cancer Investigation</i> , <b>2014</b> , 32, 144-9	2.1	74
138	Prognostic impact of alternative splicing-derived hMEN1 isoforms in resected, node-negative, non-small-cell lung cancer. <i>Oncotarget</i> , <b>2014</b> , 5, 11054-63	3.3	23
137	Signaling intermediates (MAPK and PI3K) as therapeutic targets in NSCLC. <i>Current Pharmaceutical Design</i> , <b>2014</b> , 20, 3944-57	3.3	42
136	Systemic Therapy in Melanoma <b>2014</b> , 461-474		1
135	Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments. <i>BMC Cancer</i> , <b>2013</b> , 13, 164	4.8	16
134	Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. <i>Clinical Genitourinary Cancer</i> , <b>2013</b> , 11, 471-6	3.3	19
133	Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. <i>Expert Opinion on Drug Discovery</i> , <b>2013</b> , 8, 1381-97	6.2	6
132	Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2870-8	2.2	115
131	Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 699-706	4	15
130	A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14). <i>Gynecologic Oncology</i> , <b>2013</b> , 130, 31-7	4.9	14
129	Functional and pharmacodynamic evaluation of metronomic cyclophosphamide and docetaxel regimen in castration-resistant prostate cancer. <i>Future Oncology</i> , <b>2013</b> , 9, 1375-88	3.6	11



128	Dose-dense FEC followed by dose-dense ixabepilone as neoadjuvant treatment for breast cancer patients: a feasibility study. <i>Oncologist</i> , <b>2013</b> , 18, 924-5	5.7	
127	An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study. <i>ClinicoEconomics and Outcomes Research</i> , <b>2013</b> , 5, 125-35	1.7	19
126	First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. <i>World Journal of Gastroenterology</i> , <b>2013</b> , 19, 4511-9	5.6	12
125	Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: meta-analytical estimation and implications for therapeutic strategies. <i>Cancer</i> , <b>2012</b> , 118, 1523-32	6.4	32
124	Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies. <i>Journal of Molecular Medicine</i> , <b>2012</b> , 90, 1133-44	5.5	34
123	Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy. <i>BMC Cancer</i> , <b>2012</b> , 12, 482	4.8	18
122	The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. <i>Journal of Molecular Medicine</i> , <b>2012</b> , 90, 667-79	5.5	46
121	Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer. <i>Annals of Oncology</i> , <b>2012</b> , 23, 1436-41	10.3	25
120	Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR. <i>Expert Review of Anticancer Therapy</i> , <b>2012</b> , 12, 1545-57	3.5	12
119	Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. <i>Annals of Oncology</i> , <b>2012</b> , 23, 695-700	10.3	138
118	EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy. <i>Journal of Thoracic Oncology</i> , <b>2012</b> , 7, 672-80	8.9	26
117	Molecular and genetic bases of pancreatic cancer. <i>Current Drug Targets</i> , <b>2012</b> , 13, 731-43	3	21
116	Factors associated with an individualsPdecision to withdraw from genetic counseling for BRCA1 and BRCA2 genes mutations: are personality traits involved?. <i>Familial Cancer</i> , <b>2011</b> , 10, 581-9	3	5
115	Phase I-II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2011</b> , 67, 687-93	3.5	8
114	Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2011</b> , 30, 10	12.8	68
113	Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2011</b> , 30, 54	12.8	28
112	Emerging pathways and future targets for the molecular therapy of pancreatic cancer. <i>Expert Opinion on Therapeutic Targets</i> , <b>2011</b> , 15, 1183-96	6.4	42
111	HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 2055-64	12.9	79

110	Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis. <i>Annals of Oncology</i> , <b>2011</b> , 22, 2277-85	10.3	66
109	Assessment of PTEN and PI3K status in primary breast cancer and corresponding metastases: is it worthwhile?. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 2834-5; author reply 2835	2.2	5
108	Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. <i>Annals of Oncology</i> , <b>2011</b> , 22, 625-630	10.3	118
107	Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. <i>British Journal of Cancer</i> , <b>2010</b> , 103, 1542-7	8.7	137
106	Primary ovarian cancer cells are sensitive to the proapoptotic effects of proteasome inhibitors. <i>International Journal of Oncology</i> , <b>2010</b> , 36, 707-13	4.4	3
105	Fixed-dose-rate gemcitabine: a viable first-line treatment option for advanced pancreatic and biliary tract cancer. <i>Oncologist</i> , <b>2010</b> , 15, e1-4	5.7	7
104	Early recurrence risk: aromatase inhibitors versus tamoxifen. <i>Expert Review of Anticancer Therapy</i> , <b>2010</b> , 10, 1239-53	3.5	5
103	Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1780-7	2.2	52
102	Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab. <i>Journal of Translational Medicine</i> , <b>2010</b> , 8, 36	8.5	15
101	Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials. <i>BMC Cancer</i> , <b>2010</b> , 10, 675	4.8	15
100	Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2010</b> , 29, 58	12.8	41
99	Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2010</b> , 65, 391-7	3.5	23
98	Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study. <i>Journal of Neuro-Oncology</i> , <b>2010</b> , 100, 209-15	4.8	13
97	Chordoma: clinical characteristics, management and prognosis of a case series of 25 patients. <i>BMC Cancer</i> , <b>2010</b> , 10, 22	4.8	89
96	Time to first tumor progression as outcome predictor of a second trastuzumab-based therapy beyond progression in HER-2 positive metastatic breast cancer. <i>Breast Journal</i> , <b>2010</b> , 16, 66-72	1.2	8
95	A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. <i>Journal of Clinical Investigation</i> , <b>2010</b> , 120, 681-93	15.9	249
94	Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. <i>Oncology</i> , <b>2009</b> , 76, 254-61	3.6	37
93	Darbepoetin alfa and history of thromboembolic events. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, e211; author reply e212	2.2	2



92	Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation. <i>BMC Cancer</i> , <b>2009</b> , 9, 101	4.8	24
91	Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients. <i>International Journal of Cancer</i> , <b>2009</b> , 124, 130-9	7.5	89
90	Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials. <i>Cancer</i> , <b>2009</b> , 115, 3446-56	6.4	60
89	High sensitivity of ovarian cancer cells to the synthetic triterpenoid CDDO-Imidazolidine. <i>Cancer Letters</i> , <b>2009</b> , 282, 214-28	9.9	23
88	Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials. <i>Lung Cancer</i> , <b>2009</b> , 63, 50-7	5.9	37
87	A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer. <i>Lung Cancer</i> , <b>2009</b> , 66, 365-71	5.9	71
86	Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function. <i>Clinical Pharmacokinetics</i> , <b>2009</b> , 48, 131-41	6.2	12
85	Subjective versus objective risk in genetic counseling for hereditary breast and/or ovarian cancers. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2009</b> , 28, 157	12.8	25
84	Targeting targeted agents: open issues for clinical trial design. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2009</b> , 28, 66	12.8	15
83	Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. <i>Neoplasia</i> , <b>2009</b> , 11, 1084-92	6.4	76
82	Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. <i>Neoplasia</i> , <b>2009</b> , 11, 720-31	6.4	73
81	Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer: preliminary results of a feasibility-phase II study aimed at cardiotoxicity. <i>Anti-Cancer Drugs</i> , <b>2009</b> , 20, 109-14	2.4	2
80	Pseudoprogression and MGMT status in glioblastoma patients: implications in clinical practice. <i>Anticancer Research</i> , <b>2009</b> , 29, 2607-10	2.3	23
79	Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278). <i>Clinical Breast Cancer</i> , <b>2008</b> , 8, 453-6	3	43
78	Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies. <i>Breast</i> , <b>2008</b> , 17, 499-505	3.6	43
77	A phase II study of biweekly paclitaxel (P) and gemcitabine (G), followed by maintenance weekly paclitaxel in elderly patients with advanced non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , <b>2008</b> , 60, 381-6	5.9	6
76	The withdrawal from oncogenetic counselling and testing for hereditary and familial breast and ovarian cancer. A descriptive study of an Italian sample. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2008</b> , 27, 75	12.8	14
75	Bevacizumab: one treatment for all the seasons?. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 511; author reply 511-2	2.2	1

74	COX-2 targeting in cancer: a new beginning?. <i>Annals of Oncology</i> , <b>2008</b> , 19, 1209-10	10.3	3
73	HER2 and response to paclitaxel in node-positive breast cancer. <i>New England Journal of Medicine</i> , <b>2008</b> , 358, 197; author reply 198	59.2	71
72	Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues. <i>Expert Opinion on Biological Therapy</i> , <b>2008</b> , 8, 1963-71	5.4	24
71	Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. <i>Breast Cancer Research and Treatment</i> , <b>2008</b> , 109, 231-9	4.4	119
70	Fixed dose-rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma: a dose-finding study. <i>Journal of Neuro-Oncology</i> , <b>2008</b> , 87, 79-84	4.8	12
69	Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2008</b> , 62, 717-25	3.5	35
68	Gemcitabine at fixed dose-rate in patients with advanced soft-tissue sarcomas: a mono-institutional phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2008</b> , 63, 149-55	3.5	25
67	Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II study. <i>Supportive Care in Cancer</i> , <b>2008</b> , 16, 1375-80	3.9	10
66	Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials. <i>Cancer</i> , <b>2008</b> , 112, 260-7	6.4	99
65	Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials. <i>Cancer</i> , <b>2008</b> , 113, 238-46	6.4	51
64	Taxanes and gemcitabine doublets in the management of HER-2 negative metastatic breast cancer: towards optimization of association and schedule. <i>Anticancer Research</i> , <b>2008</b> , 28, 1245-58	2.3	8
63	Sequential chemotherapy in nonsmall-cell lung cancer: cisplatin and gemcitabine followed by docetaxel. <i>Cancer</i> , <b>2007</b> , 109, 727-31	6.4	3
62	Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trials. <i>Cancer</i> , <b>2007</b> , 110, 525-33	6.4	83
61	Adjuvant chemotherapy for bladder cancer: the chance for meta-analyses comparison. <i>European Urology</i> , <b>2007</b> , 51, 576-7	10.2	4
60	A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells. <i>Gynecologic Oncology</i> , <b>2007</b> , 105, 481-92	4.9	34
59	Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2007</b> , 101, 355-65	4.4	115
58	Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , <b>2007</b> , 12, 635-55	5.4	45
57	Aromatase inhibitors in post-menopausal metastatic breast carcinoma. <i>Expert Opinion on Investigational Drugs</i> , <b>2007</b> , 16, 1023-36	5.9	3

56	Transforming growth factor-beta signaling and regulatory T cells. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 4695-6; author reply 4696-7	2.2	2
55	Re: Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized Trial. <i>Journal of the National Cancer Institute</i> , <b>2007</b> , 99, 1416	9.7	
54	Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer. <i>Oncologist</i> , <b>2007</b> , 12, 1467-9; author reply 1469-71	5.7	29
53	Re: Ovarian ablation or suppression in premenopausal early breast cancer: results from the International Adjuvant Breast Cancer Ovarian Ablation or Suppression randomized trial. <i>Journal of the National Cancer Institute</i> , <b>2007</b> , 99, 1344-5	9.7	
52	A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer. <i>Current Medical Research and Opinion</i> , <b>2007</b> , 23, 2117-23	2.5	11
51	Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 3415-20	2.2	197
50	Zoledronic acid and angiogenesis. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 6850; author reply 6850-1	12.9	5
49	Re: Age-related lobular involution and risk of breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2007</b> , 99, 571-2; author reply 572	9.7	3
48	Re: Treatment of human epidermal growth factor receptor 2 overexpressing breast cancer xenografts with multiagent human epidermal growth factor receptor targeted therapy. <i>Journal of the National Cancer Institute</i> , <b>2007</b> , 99, 1644; author reply 1644-6	9.7	1
47	Re: Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. <i>Journal of the National Cancer Institute</i> , <b>2007</b> , 99, 176; author reply 176-7	9.7	2
46	Should subgroup analysis of randomized clinical trials have a direct impact on clinical practice?. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 605-6; author reply 606-7	2.2	3
45	Old age: biologic versus chronologic. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, e8	2.2	3
44	MEK blockade converts AML differentiating response to retinoids into extensive apoptosis. <i>Blood</i> , <b>2007</b> , 109, 2121-9	2.2	36
43	Adjuvant chemotherapy for non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, S7-11	8.9	10
42	HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. <i>Current Opinion in Obstetrics and Gynecology</i> , <b>2007</b> , 19, 56-62	2.4	76
41	Troponin-T and myoglobin plus echocardiographic evaluation for monitoring early cardiotoxicity of weekly epirubicin-paclitaxel in metastatic breast cancer patients. <i>Anti-Cancer Drugs</i> , <b>2007</b> , 18, 227-32	2.4	12
40	Bio-pathologic characteristics related to chromosome 11 aneusomy and cyclin D1 gene status in surgically resected stage I and II breast cancer: Identification of an adverse prognostic profile. <i>American Journal of Surgical Pathology</i> , <b>2007</b> , 31, 247-54	6.7	5
39	Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study. <i>Anti-Cancer Drugs</i> , <b>2007</b> , 18, 687-92	2.4	5

38	Major bleedings in the comparisons between low-molecular weight heparin versus oral anticoagulant therapy for venous thromboembolism. <i>Thrombosis Research</i> , <b>2007</b> , 119, 525-9	8.2	2
37	Self-monitoring versus standard monitoring of oral anticoagulation. <i>Thrombosis Research</i> , <b>2007</b> , 119, 389-90	8.2	1
36	Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. <i>Drug Resistance Updates</i> , <b>2007</b> , 10, 81-100	23.2	62
35	Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. <i>Bone</i> , <b>2007</b> , 41, 155-6	4.7	5
34	Exemestane or tamoxifen?. <i>Lancet, The</i> , <b>2007</b> , 369, 1599; author reply 1600-1	4.0	
33	Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEMcitabine-COxib in NSCLC (GECO) study. <i>Lancet Oncology, The</i> , <b>2007</b> , 8, 500-12	21.7	80
32	The protective side of progesterone. <i>Breast Cancer Research</i> , <b>2007</b> , 9, 402	8.3	1
31	Pregnancy levels of estrogen and progesterone: the double-edged sword. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2007</b> , 16, 634; author reply 634-5	4	1
30	Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients. <i>Cancer Investigation</i> , <b>2007</b> , 25, 102-5	2.1	31
29	Comparative Gene Profiling of Acute Myeloid Leukemia (AML) and Malignant Melanoma (MEL) Cell Lines Exposed to the MEK Inhibitor PD0325901 Reveals Common Effectors of the MEK/ERK Kinase Module.. <i>Blood</i> , <b>2007</b> , 110, 3470-3470	2.2	1
28	Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-CSF in advanced gastric cancer: a multicentric phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2006</b> , 57, 59-64	3.5	12
27	Adjuvant chemotherapy in muscle-invasive bladder carcinoma: a pooled analysis from phase III studies. <i>Cancer</i> , <b>2006</b> , 106, 783-8	6.4	69
26	Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. <i>Cancer</i> , <b>2006</b> , 106, 2337-44	6.4	111
25	Does low-molecular-weight heparin influence cancer-related mortality?. <i>Annals of Oncology</i> , <b>2006</b> , 17, 1604-6	10.3	6
24	Factorial design for randomized clinical trials. <i>Annals of Oncology</i> , <b>2006</b> , 17, 1607-8	10.3	4
23	Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy: what is the appropriate use of filgrastim?. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 5618-9	2.2	2
22	Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide?. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 3048-55	2.2	33
21	Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. <i>Cancer Research</i> , <b>2006</b> , 66, 5549-54	10.1	285

20	Are dose-finding studies still necessary when targeted therapy is associated with chemotherapy?. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 4668-9; author reply 4669	2.2	
19	Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 6133-43	12.9	37
18	Does CTLA4 influence the suppressive effect of CD25+CD4+ regulatory T cells?. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 5469-70; author reply 5470-1	2.2	4
17	Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450?. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, e60-1	2.2	19
16	Human malignant mesothelioma: molecular mechanisms of pathogenesis and progression. <i>International Journal of Biochemistry and Cell Biology</i> , <b>2006</b> , 38, 2000-4	5.6	19
15	Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: pooled-analysis of 8794 patients. <i>Cancer Treatment Reviews</i> , <b>2006</b> , 32, 325-32	14.4	15
14	Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. <i>Cancer Treatment Reviews</i> , <b>2006</b> , 32, 583-7	14.4	49
13	Ten years of experience with weekly chemotherapy in metastatic breast cancer patients: multivariate analysis of prognostic factors. <i>Anti-Cancer Drugs</i> , <b>2006</b> , 17, 1193-200	2.4	5
12	Weekly docetaxel in pretreated metastatic breast cancer patients: a phase I-II study. <i>Oncology</i> , <b>2005</b> , 68, 356-63	3.6	9
11	Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 4265-74	2.2	1244
10	Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. <i>Oncology</i> , <b>2005</b> , 69, 35-43	3.6	107
9	Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma. <i>Cancer</i> , <b>2005</b> , 103, 672-9	6.4	39
8	Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree. <i>Cancer</i> , <b>2005</b> , 104, 1237-45	6.4	30
7	New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials. <i>Cancer</i> , <b>2005</b> , 104, 1335-42	6.4	32
6	Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene--amplified breast cancer cells. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 7747-56	12.9	45
5	Altered expression of FAS system is related to adverse clinical outcome in stage I-II breast cancer patients treated with adjuvant anthracycline-based chemotherapy. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 1360-5	12.9	37
4	Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. <i>Cancer</i> , <b>2004</b> , 101, 133-8	6.4	88
3	Prolonged gemcitabine infusion in advanced non-small cell lung carcinoma: a randomized phase II study of two different schedules in combination with cisplatin. <i>Cancer</i> , <b>2003</b> , 98, 337-43	6.4	44

2	Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. <i>Journal of the National Cancer Institute</i> , <b>2003</b> , 95, 1453-61	9.7	449
1	Second-Degree Type 2 Atrioventricular Block Requiring Permanent Cardiac Pacing in Patients on CDK4/6 Inhibitors: Report of Two Cases. <i>Breast Care</i> ,1-5	2.4	0